FDA’s Josh Sharfstein Takes “Acting” Title Literally
Executive Summary
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on multiple fronts, quickly stepping up regulation and taking steps toward overhauling the agency's internal culture
You may also be interested in...
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
FDA Scientists Say Plan B Decision-Makers At CDER “Should Be Removed”
Sen. Grassley releases letter and urges FDA to improve the climate for whistleblowers.